์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

MP0DPIL0TX

Pilot Holder Expansion Kit

For Pod configurations up to 5.5 m2

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ


์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

eCl@ss:
32031690
UNSPSC Code:
23151806
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

์ œํ’ˆ ์ด๋ฆ„

Pilot Holder Expansion Kit, For Pod configurations up to 5.5 m2

fitting

1.5 in. gauge port sanitary flange
1.5 in. inlet/outlet sanitary flange

compatibility

for use with Pod Filters

Quality Level

Application

For Pod configurations up to 5.5 m2

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

๋ฌธ์„œ

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

๊ด€๋ จ ์ฝ˜ํ…์ธ 

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
MP0DPIL0TX04053252562372

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.